Please assess the completion status of the following clinical trial:

Trial Title: Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age 10 to 70 years~* Diagnosis of acute AIH according to Alvarez score~* normal range of TPMT activity~* normal ACTH test~* negative pregnancy test at screening for females of childbearing potential~* written informed consent~Exclusion Criteria:~* presence of Hepatitis A, B, C, E or G virus infection~* liver cirrhosis or clinical signs of portal hypertension~* PBC~* PSC~* history of hypersensitivity to the study medication

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- budesonide (Type: EXPERIMENTAL): 3mg capsules 3x/day for 6 months
- prednisone (Type: ACTIVE_COMPARATOR): 5mg tablet, 40mg starting dose titrated to 10mg over 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).